Does disease modulating agents treat all forms of MS?

Disease-modifying agents (DMAs) can significantly reduce the frequency and severity of relapses in multiple sclerosis (MS), particularly in relapsing forms such as relapsing-remitting MS (RRMS) and secondary progressive MS with relapses. However, they are generally less effective for primary progressive MS (PPMS), where treatment options are more limited and DMAs may not provide the same benefits. While these agents can help manage the disease, they do not treat all forms of MS equally. Individual treatment plans should be tailored to the specific type and progression of the disease.